INTRABEAM术中放疗治疗23例不能切除胰腺癌疗效观察.docVIP

INTRABEAM术中放疗治疗23例不能切除胰腺癌疗效观察 　　【摘要】目的：探讨INTRABEAM术中放疗治疗不能切除胰腺癌的疗效及安全性。方法：回顾性分析本科2009年1-12月行胰腺癌姑息手术并术中放疗的23例胰腺癌患者的临床资料，照射量20~30 Gy，观察围手术期情况及术后3年生存情况。结果：所有患者无住院期间死亡，围手术期无严重手术及放疗并发症。腹痛或腰背痛的总有效率为95%。本组1年生存率52%，2年生存率13%，中位生存期15.5个月。结论：INTROBEAM术中放疗安全有效，能够有效控制晚期胰腺癌患者的疼痛症状，改善生活质量，但并不明显延长患者生存期。 　　【关键词】胰腺癌；术中放疗 　　 　　Clinical Observation of 23 Cases of Unresectable Pancreatic Cancer Treated by INTRABEAM Intraoperative Radiotherapy/CEN Jun-hua，FENG Ju-tao，CHEN Jin-song，et al.// Medical Innovation of China，2013，10（20）：103-104 　　【Abstract】Objective：To discuss the efficacy and safety of the INTRABEAM intraoperative radiotherapy in the teatment of unresectable pancreatic cancer.Method：Retrospectively analyze the clinical data of 23 patients with pancreatic cancer from January to December in 2009，who were given pancreatic cancer palliative operation combined with intraoperative radiotherapy.the given exposure was 20-30 Gy，observed the peri operation period and the Survival of 3 years.Result：All patients had no in-hospital death during operation period， no severe complications of radiotherapy and operation complication occured，Abdominal or back pain in the total efficiency was 95%. The 1 year survival rate was 52%， 2 year survival rate was 13%， the median survival period was 15.5 months.Conclusion：Therapy in INTROBEAM is Safe and effective， it can effectively control of patients with advanced pancreatic cancer pain symptoms， improve the quality of life， but it can not significantly prolong the survival time of the patients. 　　【Key words】 Pancreatic cancer；Intraoperative radiotherapy 　　First-author’s address： The First Affiliated Hospital of Guangzhou Medical College，Guangzhou 510120，China 　　doi：10.3969/j.issn.1674-4985.2013.20.051 　　近年胰腺癌被称为恶性肿瘤的“新癌王”，起病隐匿，大多数在确诊时已属晚期，失去了根治性手术的机会。对不能手术的晚期胰腺癌患者，NCCN指南推荐放化疗为主的综??治疗[1]。本研究探索姑息性手术结合术中放疗治疗晚期不可切除胰腺癌，发现其可明显减轻患者疼痛，改善生存质量，现报道如下。 　　1资料与方法 　　1.1 一般资料本科2009年1-12月收治的45例胰腺癌患者中共有30例患者术中探查发现肿瘤晚期不可切除，7例患者拒绝术中放疗。23例入组患者均无术前放化疗治疗史；其中22例经术